Review of Pharmacotherapeutic Targets in Alzheimer’s Disease and Its Management Using Traditional Medicinal Plants
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. While there is currently no cure for AD, several pharmacotherapeutic targets and management strategies have been explored. Additionally, traditional medicinal plants have gained attention for their potential role in AD management. Pharmacotherapeutic targets in AD include amyloid-beta (Aβ) aggregation, tau protein hyperphosphorylation, neuroinflammation, oxidative stress, and cholinergic dysfunction. Traditional medicinal plants, such as Ginkgo biloba, Huperzia serrata, Curcuma longa (turmeric), and Panax ginseng, have demonstrated the ability to modulate these targets through their bioactive compounds. Ginkgo biloba , for instance, contains flavonoids and terpenoids that exhibit neuroprotective effects by reducing Aβ deposition and enhancing cerebral blood flow. Huperzia serrata , a natural source of huperzine A, has acetylcholinesterase-inhibiting properties, thus improving cholinergic function. Curcuma longa , enriched with curcumin, exhibits anti-inflammatory and antioxidant effects, potentially mitigating neuroinflammation and oxidative stress. Panax ginseng’s ginsenosides have shown neuroprotective and anti-amyloidogenic properties. The investigation of traditional medicinal plants as a complementary approach to AD management offers several advantages, including a lower risk of adverse effects and potential multi-target interactions. Furthermore, the cultural knowledge and utilization of these plants provide a rich source of information for the development of new therapies. However, further research is necessary to elucidate the precise mechanisms of action, standardize preparations, and assess the safety and efficacy of these natural remedies. Integrating traditional medicinal-plant-based therapies with modern pharmacotherapies may hold the key to a more comprehensive and effective approach to AD treatment. This review aims to explore the pharmacotherapeutic targets in AD and assess the potential of traditional medicinal plants in its management. Keywords: Alzheimer’s disease, acetylcholinesterase, amyloid beta, tau protein, traditional medicine, Ayurvedic herbs, acetylcholinesterase inhibitors, neurodegenerative disorders, cognition
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“56,57 Necroptosis and NLRP3 inflammasome are the common simulatory factors for neuroinflammation found in the AD brain which leads to apoptosis and autophagy resulting in neuronal cell death.”
BackgroundToxic Metals and Oxidative Stress Part I: Mechanisms Involved in Me-tal induced Oxidative Damage
Nuran Ercal, B. S. P., Hande Gurer-Orhan, B. S. P., & Nukhet Aykin-Burns, B. S. P. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013394831 · Cited by 1,944
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308 · cited 1×
“80 These types of receptors are associated with the low-density lipoprotein (LDL) gene family and are situated on chromosome number 19.”
BackgroundInflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 1×
“90 A study further reported that augmented COX-2 expression causes the NMDA-mediated receptor excitotoxicity.”
BackgroundAn Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases
Teleanu, D. M., Niculescu, A.-G., Lungu, I. I., Radu, C. I., Vladâcenco, O., Roza, E., Costăchescu, B., Grumezescu, A. M., & Teleanu, R. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115938 · Cited by 1,085
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
Acetylcholinesterase inhibitors from plants
Mukherjee, P. K., Kumar, V., Mal, M., & Houghton, P. J. (2007) · Phytomedicine · doi:10.1016/j.phymed.2007.02.002 · Cited by 809
Allan Butterfield, D. (2002) · Free Radical Research · doi:10.1080/1071576021000049890 · Cited by 786
Pharmacological properties of Salvia officinalis and its components
Ghorbani, A., & Esmaeilizadeh, M. (2017) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2016.12.014 · Cited by 677
Lyras, L., Cairns, N. J., Jenner, A., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052061.x · Cited by 531 · cited 1×
“71 Numerous causes, including defective mitochondrial energy metabolism, 75 DNA oxidation, 76 Ca 2+ homeostasis, abnormal protein accumulation, altered proteasome functions, membrane damage, and an abundance of trace elements and transition metals (including aluminum, mercury, copper, zinc, and…”
BackgroundCurrent understanding of metal ions in the pathogenesis of Alzheimer’s disease
Wang, L., Yin, Y.-L., Liu, X.-Z., Shen, P., Zheng, Y.-G., Lan, X.-R., Lu, C.-B., & Wang, J.-Z. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00189-z · Cited by 454
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336 · cited 1×
“60 PSEN1 and PSEN2 encode for presenilin 1 and 2 genes, respectively.”
BackgroundSharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331 · cited 2×
“15 The inflammatory mediators also stimulate the MAP kinase and cyclin-dependent kinase-5 (CDK-5) and subsequently produce tau phosphorylation.”
BackgroundSelf-citationManagement of oxidative stress and other pathologies in Alzheimer’s disease
Simunkova, M., Alwasel, S. H., Alhazza, I. M., Jomova, K., Kollar, V., Rusko, M., & Valko, M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02538-y · Cited by 303 · cited 1×
“128 Additionally, the FDA now only approves a few medicines for the treatment and diagnosis of AD.”
BackgroundEmerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Cognitive enhancement and neuroprotective effects of Bacopa monnieri in alzheimer’s disease model
Uabundit, N., Wattanathorn, J., Mucimapura, S., & Ingkaninan, K. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.09.056 · Cited by 282
APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease
Parhizkar, S., & Holtzman, D. M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101594 · Cited by 255 · cited 1×
“88 Plaque deposition promotes microglia, which are susceptible to neuronal damage and neurodegenerative diseases, to become inflamed.”
BackgroundVladimir-Knežević, S., Blažeković, B., Kindl, M., Vladić, J., Lower-Nedza, A., & Brantner, A. (2014) · Molecules · doi:10.3390/molecules19010767 · Cited by 238
The cholinergic innervation of the human cerebral cortex.
Mesulam, M.-M. (2004) · Progress in Brain Research · doi:10.1016/s0079-6123(03)45004-8 · Cited by 211 · cited 1×
“34 In addition, the nucleus basalis of Meynert (NBM) cholinergic neurons are located in the substantia innominate and along the ventral extent of the basal forebrain.”
BackgroundLimpeanchob, N., Jaipan, S., Rattanakaruna, S., Phrompittayarat, W., & Ingkaninan, K. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.07.039 · Cited by 206
Dhanasekaran, M., Holcomb, L. A., Hitt, A. R., Tharakan, B., Porter, J. W., Young, K. A., & Manyam, B. V. (2009) · Phytotherapy Research · doi:10.1002/ptr.2405 · Cited by 175
Clitoria ternatea root extract enhances acetylcholine content in rat hippocampus
Rai, K. S., Murthy, K. D., Karanth, K. S., Nalini, K., Rao, M. S., & Srinivasan, K. K. (2002) · Fitoterapia · doi:10.1016/s0367-326x(02)00249-6 · Cited by 113
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Geula, C., Dunlop, S. R., Ayala, I., Kawles, A. S., Flanagan, M. E., Gefen, T., & Mesulam, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15471 · Cited by 102 · cited 1×
“38,39 Acetyl CoA, which is produced from the breakdown of glucose (glycolysis) or citrate (pyruvate-oxidase system), catalyzes the biosynthesis of ACh.”
BackgroundAntiamnesic Effects of Desmodium gangeticum in Mice
JOSHI, H., & PARLE, M. (2006) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.126.795 · Cited by 70
Traditional used Plants against Cognitive Decline and Alzheimer Disease
Eckert, G. P. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00138 · Cited by 47
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29
Davidson, R., Krider, R. I., Borsellino, P., Noorda, K., Alhwayek, G., & Vida, T. A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110553 · Cited by 17 · cited 1×
“63 The excessive hyperphosphorylation of tau protein in AD is facilitated by the overstimulation of kinases and inactivation of phosphatases.”
BackgroundKhojah, H., & Edrada-Ebel, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.06.044 · Cited by 8
Cited by
LncRNAs Orchestrating Neuroinflammation: A Comprehensive Review
Esmaeili, A., Yazdanpanah, N., & Rezaei, N. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01538-0 · Cited by 24
“Despite copious amounts of research conducted on therapeutic techniques in AD, there is no solid therapy for AD; however, traditional medicinal plants have obtained attention in the management of AD (Tripathi et al. 2024).”
Rouhi, N., Chakeri, Z., Ghorbani Nejad, B., Rahimzadegan, M., Rafi Khezri, M., Kamali, H., & Nosrati, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37533 · Cited by 20
“The accumulation of amyloid beta (A β ) plaques and neurofibrillary tangles (NFTs) composed of phosphorylated tau protein in the brain (hippocampus) cells are considered the hallmark lesions of AD [8,27,30,31].”
BackgroundAssociation of APOC1 with cortical atrophy during conversion to Alzheimer’s disease
Oh, S., Kim, S., Kim, J. P., Seo, S. W., Park, B.-Y., & Park, H. (2025) · GeroScience · doi:10.1007/s11357-025-01695-6 · Cited by 4
Metadata
- Authors
- Tripathi, P., Lodhi, A., Rai, S., Nandi, N., Dumoga, S., Yadav, P., Tiwari, A., Singh, S., El-Shorbagi, A.-N., & Chaudhary, S.
- Venue
- Degenerative Neurological and Neuromuscular Disease
- Publisher
- Informa UK Limited
- Published
- 2024-05
- Volume
- Volume 14
- Pages
- 47-74
- ISSN
- 1179-9900 (ISSN-L)
- OpenAlex
- W4397032861
- Cited by
- 146
- References
- 32
- FWCI
- 61.10
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.